Real-world cost-effectiveness in chronic myeloid leukaemia: The price of success during four decades of development from non-targeted treatment to imatinib

Ohm L, Lundqvist A, Dickman P, Hoglund M, Persson U, Stenke L, Steen Carlsson K and Bjorkholm M

Imatinib is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, primarily chronic myelogenous leukemia (CLM). This study evaluates clinical outcome and cost-effectiveness of imatinib in CML-patients. A lifetime cost-effectiveness model was developed and Swedish registry data on CML-patients diagnosed 1973-2008 was applied. The data, covering four decades, revealed dramatically improved survival in CML, paralleled by ICER levels generally accepted by authorities.

Read more

Leukemia & Lymphoma 2015; 56(5): 1385 - 1391
DOI: 10.3109/10428194.2014.953141